» Articles » PMID: 24134199

Staging, Prognostic Factors and Adjuvant Therapy of Intrahepatic Cholangiocarcinoma After Curative Resection

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2013 Oct 19
PMID 24134199
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma (ICC) after curative resection were not clear. We aim to analyse prognostic factors after curative resection and evaluate adjuvant therapy and survival based on the new staging system.

Methods: A retrospective analysis of 283 patients who underwent surgical exploration for ICC was performed. Staging was performed according to the 7th edition AJCC staging manual. Univariate and multivariate analyses were used to evaluate independent prognostic factors.

Results: The difference for OS at different TNM stages after R0 resection was significant (P < 0.001). Despite regional lymph node metastasis, tumour number and vascular invasion, serum GGT level was also an independent prognostic factor for OS of patients after R0 resection. The incidence of biliary and vascular invasion was significantly higher in high GGT group than in normal GGT group. Factors predictive of recurrence were multiple tumours and regional lymph node metastasis. After R0 resection, adjuvant TACE not only did not improve the OS of patients at TNM stage I (P = 0.508), but significantly promoted recurrence of these patients (P = 0.006). Only patients at TNM stage II, III and IV benefited from adjuvant TACE for longer survival, while the recurrence rates were not affected.

Conclusions: The new staging system can predict the survival of ICC patients after R0 resection. High GGT level may be suggestive of biliary and vascular invasion and was an independent risk factor for OS after R0 resection. Adjuvant TACE may be indicated only for patients at advanced stages for better survival.

Citing Articles

Update on Resection Strategies for Hepatocellular Carcinoma: A Narrative Review.

Lee J, Choi H, Kim J, Lee T, Yoon Y Cancers (Basel). 2024; 16(23).

PMID: 39682279 PMC: 11640626. DOI: 10.3390/cancers16234093.


Epidemiology of biliary tract cancer in China: A narrative review.

Zhou J, Tan G, Zhang L, Xie G, Chen W, Zhang X Chin J Cancer Res. 2024; 36(5):474-488.

PMID: 39539810 PMC: 11555199. DOI: 10.21147/j.issn.1000-9604.2024.05.02.


Mining the interpretable prognostic features from pathological image of intrahepatic cholangiocarcinoma using multi-modal deep learning.

Ding G, Tan W, Lin Y, Ling Y, Huang W, Zhang S BMC Med. 2024; 22(1):282.

PMID: 38972973 PMC: 11229270. DOI: 10.1186/s12916-024-03482-0.


Precision therapy for intrahepatic cholangiocarcinoma: A case report on adjuvant treatment in a recurrent patient after surgery and literature review.

Ying B, Tang T, Zhang L, Xiong J, Zhao K, Li J Oncol Lett. 2024; 27(2):56.

PMID: 38192668 PMC: 10773204. DOI: 10.3892/ol.2023.14189.


Using immunovascular characteristics to predict very early recurrence and prognosis of resectable intrahepatic cholangiocarcinoma.

Xu Y, Li Z, Zhou Y, Yang Y, Ouyang J, Li L BMC Cancer. 2023; 23(1):1009.

PMID: 37858111 PMC: 10588260. DOI: 10.1186/s12885-023-11476-z.